Multiple confirmed responses and durable disease control observed
Emerging differentiated safety profile enables further exploration at higher doses
Ongoing Phase 2 clinical study of monotherapy and in combination with a PD-1 inhibitor
SAN DIEGO, Dec. 13, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (NASDAQ:BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today is hosting a virtual R&D Day on its novel conditionally and reversibly active antibody targeting CTLA-4, BA3071. BA3071 is in Phase 2 development as a potential therapeutic for multiple solid tumor indications known to be responsive to CTLA-4 treatment as monotherapy, and in combination with a PD-1 blocking agent.
The event will feature Omid Hamid, MD, Chief, Translational Research and Immunotherapy, and Director, Melanoma Therapeutics at The Angeles Clinic and Research Institute, and highlights Phase 1 dose escalation trial results for BA3071.
"The initial results from our Phase 1 dose escalation clinical trial showcases the innovative tumor selective, CAB platform with our CAB-CTLA-4 antibody," said Jay M. Short, Ph.D., Chairman, Chief Executive Officer and co-founder of BioAtla, Inc. "We observed confirmed clinical responses and prolonged stable disease among 18 patients treated with BA3071 in combination with PD-1. In addition, the relatively low incidence of immune-related adverse events suggests our CAB antibody has the potential to address the current limitations of CTLA-4-targeted therapies."
"CTLA-4 therapies can prolong the survival of patients with metastatic melanoma and other cancers, but often cause severe immune related side effects," said Dr. Hamid. "Now having observed clinical benefit with acceptable tolerability among the first 18 patients treated with BA3071 in our dose escalation trial, I'm encouraged by the promise that this novel approach holds."
Key R&D Day Topics and Highlights
- Preclinical data review of targeted, pH-dependent binding of BA3071 in the tumor microenvironment demonstrated complete tumor regression following BA3071 treatment. Exposure levels of BA3071 were similar to that of ipilimumab analog, with significantly less GI toxicity when combined with nivolumab in a non-human primate model.
- A Phase 1 dose-escalation study evaluated BA3071 monotherapy followed by combination with nivolumab, conducted in 18 patients who had prior PD-1 failure and a median of at least three prior lines of treatment
- Across the 6 cohorts (n = 16 evaluable patients), best overall response observed with two confirmed responses (one complete response [CR] and one partial response [PR]); nine stable disease (SD)
- One uveal melanoma patient remains on treatment for more than 12 cycles
- Two cutaneous melanoma patients remain on treatment for more than 14 and 17 cycles, respectively
- One small-cell lung carcinoma (SCLC) patient continues on ...
- Across the 6 cohorts (n = 16 evaluable patients), best overall response observed with two confirmed responses (one complete response [CR] and one partial response [PR]); nine stable disease (SD)